Compare Garmin Ltd. (GRMN) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs Pfizer Inc — how do they compare? Garmin Ltd. trades at $267.45 (market cap $51.77B), while Pfizer Inc trades at $28.18 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 3.1× Garmin Ltd.'s market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 83 Days and Pfizer Inc for 158 Days on average.
| GRMN | PFE | |
|---|---|---|
Market Cap | $51.77B | $158.56B |
Volume | 961,398 | 44,138,282 |
Sector | Technology | Health |
52-Week High | $313.16 | $29.02 |
52-Week Low | $187.10 | $23.67 |
Typical Hold Time | 83 Days | 158 Days |
Enterprise Value | $49.28B | $210.06B |
Dividend Yield | 1.56% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $268.51, down 2.77% today, amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue and net income show steady growth, reaching $7.25B and $1.66B in 2025, respectively, supported by strong profitability margins. Recent news highlights product innovations and industry awards, reinforcing its market position.
The outlook remains positive given earnings momentum and a consensus price target of $320.25, implying significant upside. However, high valuation ratios and bearish technical indicators pose near-term risks. Investors should weigh strong fundamentals against potential volatility and competitive pressures in the consumer electronics space.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
